The ALAS1 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal cell population derived from the human HAP1 cell line, featuring targeted disruption of the ALAS1 gene. This loss-of-function model enables investigations into the first and rate-limiting step of heme biosynthesis, catalyzed by 5-aminolevulinate synthase 1. The polyclonal nature provides a heterogeneous knockout pool, reflecting a mixed population of gene-edited cells, suitable for bulk functional studies without single-cell clonal expansion.
HAP1 is a near-haploid, adherent human cell line originating from KBM-7 chronic myeloid leukemia cells, widely employed in genetic screens and functional genomics due to its haploid karyotype, which simplifies gene editing and phenotypic analysis. The HAP1 background offers a consistent platform for interrogating gene function, and its CML origin provides a context for studying metabolic pathways relevant to cancer biology and hematopoietic cells.
ALAS1 encodes the ubiquitous isoform of 5-aminolevulinate synthase, located in the mitochondrial matrix, where it condenses glycine and succinyl-CoA to form 5-aminolevulinate, committing metabolites to porphyrin synthesis. Enzyme levels are tightly controlled by heme-mediated feedback inhibition and regulated proteolysis involving mitochondrial proteases such as LONP1, CLPX, and CLPP. Upstream regulators include NRF2, PGC-1??, and HSP90, linking ALAS1 expression to oxidative stress and energy metabolism. Downstream, ALAS1 provides heme for incorporation into cytochrome P450 enzymes, hemoglobin, catalase, and cytochrome c, thereby influencing drug metabolism, antioxidant defense, and electron transport. Key interacting partners??SUCLG1, LONP1, HSP70??and pathway components (ALAD, HMBS, UROS, UROD, CPOX, PPOX, FECH) coordinate heme synthesis.
In the HAP1 model, ALAS1 knockout disrupts heme production, potentially impairing mitochondrial respiration and cytochrome P450-dependent drug metabolism, thus offering a system to dissect porphyria-like phenotypes and heme-deficiency disorders. The haploid nature of HAP1 permits efficient knockout and facilitates genotype?Cphenotype correlation in metabolic studies. Given the CML background, this model also supports exploration of heme metabolism in leukemic cell proliferation and adaptation to oxidative stress.
Researchers can employ these knockout cells to examine heme biosynthesis regulation via Western blotting for ALAS1, RT-qPCR, heme colorimetric assays, and ALAS enzyme activity measurements. Further, mitochondrial respiration assays, cytochrome c oxidase activity tests, and flow cytometric assessment of mitochondrial mass can reveal functional consequences. Metabolite profiling of porphyrins and co-immunoprecipitation with LONP1 enable detailed mechanistic dissections. This cell model aids investigations into altered drug metabolism, mitochondrial iron management, and cancer cell metabolism. For inquiry, contact Ascent Research.
